Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Dermatitis symbols : Lly save search
More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study
Published: 2024-03-10 (Crawled : 20:20) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -1.3%
H: 0.61%
C: -2.37%
dermatitis skin study
Almirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic Dermatitis
Published: 2023-11-17 (Crawled : 18:00) - biospace.com/
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
|
| O: -1.71%
H: 0.0%
C: 0.0%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: 0.0%
ebglyss dermatitis approval
Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with Lilly's lebrikizumab monthly maintenance dosing at two years
Published: 2023-10-20 (Crawled : 11:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -1.52%
H: 0.0%
C: 0.0%
dermatitis skin
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
Published: 2023-10-13 (Crawled : 11:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 1.15%
H: 0.0%
C: 0.0%
dermatitis
Global Report on Seborrheic Dermatitis Market Size & Share Worth USD 5 billion, to Record a 11.1% CAGR by 2030 | Seborrheic Dermatitis Industry Trends, Segmentation, Analysis & Forecast by FnF
Published: 2023-02-01 (Crawled : 17:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.4%
H: 0.92%
C: -0.06%
global report dermatitis market
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress
Published: 2022-09-07 (Crawled : 06:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.64%
H: 1.18%
C: 0.92%
NKTR | $1.285 -2.65% 630K
|
Health Technology
|
| O: -1.86%
H: 5.15%
C: 2.98%
ly3471 dermatitis therapeutics psoriasis
Eli Lilly's Phase III Atopic Dermatitis Drug Touts Significant Skin Clearance
Published: 2022-06-07 (Crawled : 15:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: 0.0%
clearance drug dermatitis skin
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly's Lebrikizumab Atopic Dermatitis Monotherapy Trials
Published: 2022-06-07 (Crawled : 05:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -3.62%
H: 0.0%
C: 0.0%
clearance trials dermatitis year skin one
Lilly's Lebrikizumab Combined with Topical Corticosteroids Showed Significant Improvements in Disease Severity for Atopic Dermatitis
Published: 2022-04-11 (Crawled : 14:20) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.45%
H: 0.21%
C: -1.32%
disease dermatitis
Majority of Patients Treated with Lebrikizumab Achieved Skin Clearance in Lilly's Pivotal Phase 3 Atopic Dermatitis Studies
Published: 2022-03-26 (Crawled : 16:20) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
| Email alert
Add to watchlist
clearance dermatitis skin phase 3
Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis
Published: 2022-01-28 (Crawled : 14:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.33%
H: 3.25%
C: 3.2%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: -0.2%
H: 3.93%
C: 3.89%
olumiant fda atopic dermatitis program dermatitis baricitinib phase 3 lupus
Lilly's lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study
Published: 2021-12-21 (Crawled : 07:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.2%
H: 0.74%
C: 0.33%
atopic dermatitis dermatitis skin phase 3
Global Atopic Dermatitis Drugs Market Report 2021: Rising Incident of Food Allergies Intensifying Atopic Dermatitis - Forecast to 2026
Published: 2021-08-19 (Crawled : 23:00) - prnewswire.com
NVS | $93.81 1.34% 1.2M
|
Health Technology
|
| O: -0.56%
H: 0.87%
C: 0.7%
GSK | $39.605 0.85% 790K
|
Health Technology
|
| O: -0.17%
H: 0.67%
C: 0.26%
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
BMY | $48.89 1.22% 5.1M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
BHC | $8.63 0.35% 1.5M
|
Health Technology
|
| O: 0.04%
H: 1.71%
C: 0.18%
ABBV | News | $166.43 1.08% 2M
|
Health Technology
|
| O: 0.14%
H: 1.16%
C: 0.61%
SNY | News | $46.545 2.55% 2.3M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
food dermatitis drug atopic dermatitis
Lilly's lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
Published: 2021-08-16 (Crawled : 07:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.33%
H: 2.03%
C: 1.91%
dermatitis phase 3 skin trial atopic dermatitis clearance
Lilly and Incyte provide update on supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
Published: 2021-07-16 (Crawled : 14:00) - prnewswire.com
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: 0.3%
H: 0.44%
C: -2.37%
new drug baricitinib treatment dermatitis drug atopic dermatitis
OLUMIANT® Showed Significant Improvements in the Severity and Extent of Atopic Dermatitis and Other Patient-Reported Outcomes in Phase 3 Study Analyses
Published: 2021-04-23 (Crawled : 17:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.01%
H: 1.12%
C: 0.9%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: 0.5%
H: 1.3%
C: 1.16%
dermatitis phase 3 atopic dermatitis
FDA Extends Supplemental NDA Review Period for Lilly and Incyte’s Atopic Dermatitis Drug
Published: 2021-04-07 (Crawled : 18:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: 0.05%
H: 0.15%
C: -0.32%
fda dermatitis drug atopic dermatitis
Lilly and Incyte communicate review extension of supplemental New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
Published: 2021-04-06 (Crawled : 23:00) - biospace.com/
LLY | $727.48 -2.48% 2M
|
Health Technology
|
| O: -0.11%
H: 0.51%
C: -1.02%
INCY | $52.45 -0.7% 530K
|
Health Technology
|
| O: -0.3%
H: 1.07%
C: 0.22%
new drug treatment dermatitis drug baricitinib atopic dermatitis
Gainers vs Losers
| 73% | 27% |
Top 10 Gainers
AGBA | News | $1.27 217.5% 120M
|
Finance
EGOX | $0.054 50.0% 290M
|
RWOD | $10.52 31.56% 5.9M
|
n/a
ZCMD | $1.905 31.38% 30M
|
Commercial Services
NVFY | $2.71 28.44% 31M
|
Consumer Durables
MRDB 4 | $0.536 27.65% 2M
|
n/a
BSFC | $0.0822 27.64% 75M
|
Manufacturing
INDO | $5.1 25.0% 15M
|
Energy Minerals
CHRO | $1.53 24.9% 100K
|
n/a
AULT | $0.2998 23.83% 53M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.